KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Takeda Pharmaceutical (TAK) Equity Ratio (2018 - 2025)

Historic Equity Ratio for Takeda Pharmaceutical (TAK) over the last 8 years, with Q3 2025 value amounting to 0.49.

  • Takeda Pharmaceutical's Equity Ratio changed N/A to 0.49 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.49, marking a year-over-year change of. This contributed to the annual value of 0.49 for FY2025, which is 111.13% up from last year.
  • Takeda Pharmaceutical's Equity Ratio amounted to 0.49 in Q3 2025.
  • Takeda Pharmaceutical's 5-year Equity Ratio high stood at 0.49 for Q3 2025, and its period low was 0.4 during Q1 2021.
  • Moreover, its 5-year median value for Equity Ratio was 0.46 (2022), whereas its average is 0.46.
  • Its Equity Ratio has fluctuated over the past 5 years, first soared by 1277.56% in 2021, then surged by 111.13% in 2025.
  • Takeda Pharmaceutical's Equity Ratio (Quarter) stood at 0.42 in 2021, then rose by 8.93% to 0.46 in 2022, then increased by 3.65% to 0.47 in 2023, then increased by 3.6% to 0.49 in 2024, then increased by 0.35% to 0.49 in 2025.
  • Its Equity Ratio stands at 0.49 for Q3 2025, versus 0.49 for Q2 2025 and 0.49 for Q1 2025.